Eli Lilly and Company (LLY)
| Market Cap | 837.17B +5.5% |
| Revenue (ttm) | 65.18B +44.7% |
| Net Income | 20.64B +94.9% |
| EPS | 22.95 +96.0% |
| Shares Out | 894.82M |
| PE Ratio | 40.77 |
| Forward PE | 26.99 |
| Dividend | $6.92 (0.74%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2,725,883 |
| Open | 945.00 |
| Previous Close | 954.52 |
| Day's Range | 930.02 - 957.69 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 1,200.60 (+28.33%) |
| Earnings Date | Apr 30, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,200.6, which is an increase of 28.33% from the latest price.
News
India's 'Mounjaro brides': weight-loss injections become part of pre-wedding preparation
Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India.
A new weight-loss pill is here, and it could reshape the GLP-1 market
A new GLP-1 pill is about to hit the market. On Wednesday, Eli Lilly and Co. announced that its new GLP-1 pill, Foundayo, was approved by the Food and Drug Administration (FDA) for use in adults with ...
MSFT, AVGO, LLY & Other Stock Market Opportunities Amid U.S.-Iran War
There's always opportunity in markets if you know where to look, says Tiffany McGhee. She offers insight into how her firm positions portfolios in times of profound volatility, including now as the U....
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC ...
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
Eli Lilly And Company (NYSE: LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopolitical tensions weigh on broader markets.
Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
Oral Wegovy demonstrated "significantly greater mean weight loss" than Lilly's rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday. Novo's findings evaluated previously publi...
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
Eli Lilly's newly approved weight-loss pill is expected to generate billions in sales as soon as this year, with analysts betting it will quickly narrow Novo Nordisk's head start in the oral market.
Novo VP Weighs In on Approval of Lilly's Obesity Pill
Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More ...
Pricing and availability of Novo, Lilly's weight-loss drugs
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expan...
VIEW Lilly gets FDA nod for oral obesity pill, analysts see strong uptake potential
The U.S. Food and Drug Administration has approved Eli Lilly's weight-loss pill, bringing another oral alternatives to a market dominated by injectables and intensifying competition with Novo Nordisk...
Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says
Eli Lilly opposes the White House's push to codify 'Most Favored Nations' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...
FDA Approves Eli Lilly's Weight Loss Pill—Second Weight GLP-1 Drug In Pill Form
The Food and Drug Administration has approved Foundayo, Eli Lilly's new GLP-1 pill to treat weight loss—the second oral weight loss drug to hit the market after Novo Nordisk's Wegovy was greenlit last...
America has a new weight-loss drug, and it's a pill
The Food and Drug Administration on Wednesday approved Foundayo, an oral GLP-1 medication that is expected to produce tens of billions of dollars at its peak. Lilly's stock LLY+4.12% jumped 5% after t...
Eli Lilly CEO: Our pill supply can 'reach the planet'
Eli Lilly Chair & CEO Dave Ricks tells CNBC's Angelica Peebles that with the approval of the company's GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the glo...
Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market.
Eli Lilly's Foundayo will be available to patients through the drugmaker's online pharmacy.
Lilly's weight-loss pill wins US approval
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight-loss pill, making it the second to market after Novo Nordisk's oral Wegovy, as the companies fight to capture more...
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
Cramer's Mad Dash -- Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® with...
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenienc...
Stock Of The Day: Where Will Eli Lilly Turn?
Some people believe the market is random. They think it isn't possible to time the market.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that...
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug ...
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under th...